Search results for "Anemia"

showing 10 items of 352 documents

Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes.

1997

Bone marrow (BM) failure associated with cytomegalovirus (CMV) infection is a feared complication after clinical BM transplantation. Experiments in long-term BM cultures have indicated that BM stromal cells (BMSC) are targets of productive CMV infection, but an in situ infection of BM stroma remained to be documented, and the pathomechanism is open to question. Here we describe a murine in vivo model of lethal CMV aplastic anemia (CMV-AA). The reconstitution of hematopoietic progenitor cells expressing stem cell factor (SCF) receptor was found to be defective in CMV-AA. While murine CMV replication in permissive parenchymal tissues is cytolytic, the hematopoietic cord was found to be a site…

MaleStromal cellImmunologyGene ExpressionStem cell factorBiologyHematopoietic Cell Growth FactorsMicrobiologyMiceBone MarrowVirologyGranulocyte Colony-Stimulating FactormedicineAnimalsRNA MessengerAplastic anemiaMice Inbred BALB CStem Cell FactorInterleukin-6Hematopoietic Cell Growth FactorsBone marrow failureAnemia Aplasticmedicine.diseaseHematopoiesisTransplantationHaematopoiesisProto-Oncogene Proteins c-kitmedicine.anatomical_structureInsect ScienceImmunologyCytomegalovirus InfectionsFemaleBone marrowResearch Article
researchProduct

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

2018

Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for these beneficial effects remain undetermined. The aim of this study is to quantify cardiac magnetic resonance changes in myocardial iron content after administration of intravenous FCM in patients with heart failure and iron deficiency and contrast them with parameters of heart failure severity. This is a multicenter, double-blind, randomized study. Fifty patients with stable symptomatic heart failure, left ventricular ejection fraction <50%, and iron deficiency will be r…

MaleTime FactorsMyocardial ironheart failure030204 cardiovascular system & hematologyFerric CompoundsSeverity of Illness IndexVentricular Function Left030218 nuclear medicine & medical imaginglaw.invention0302 clinical medicineiron deficiencyClinical ProtocolsQuality of lifeRandomized controlled triallawCardiac Magnetic Resonance Ferric Carboxymaltose Heart Failure Iron Deficiency Myocardial IronInfusions IntravenousEjection fractionAnemia Iron-DeficiencyGeneral MedicineIron deficiencyferric carboxymaltoseTreatment OutcomeResearch DesignCardiologyFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyTrial DesignsMagnetic Resonance Imaging CinePlacebocardiac magnetic resonance03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltosemyocardial ironAgedHeart Failurebusiness.industryMyocardiumStroke VolumeRecovery of Functionmedicine.diseaseSpainHeart failureHematinicsQuality of Lifebusiness
researchProduct

Acute normovolaemic anaemia prevents ethanol-induced gastric damage in rats through a blood flow related mechanism.

1994

The aim of the study was to assess whether changes in gastric mucosal blood flow induced by acute normovolaemic anaemia influence the susceptibility of the gastric mucosa to ethanol-induced damage, and the relationship of these changes with nitric oxide biosynthesis. Acute normovolaemic anaemia, promoted by exchanging 3 ml of blood by a plasma expander, induced a significant increase in gastric mucosal blood flow measured by hydrogen gas clearance, without changes in arterial blood pressure. After intragastric 60% ethanol administration, gastric blood flow was still significantly higher in anaemic than in control rats, and this was associated with a lower macroscopic and microscopic gastric…

MaleVasopressinGastrointestinal DiseasesVasopressinsNitric oxide biosynthesisPharmacologyArginineNitric OxideNitric oxideRats Sprague-Dawleychemistry.chemical_compoundmedicineGastric mucosaAnimalsPharmacologyEthanolomega-N-MethylarginineEthanoldigestive oral and skin physiologyAnemiaGeneral MedicineBlood flowRatsmedicine.anatomical_structureBlood pressurechemistryGastric MucosaAnesthesiamedicine.symptomVasoconstrictionBlood Flow VelocityNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

2013

International audience; Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship of incident anemia with triple therapy. A total of 1,097 patients received a 4-week lead-in of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC plus PegIFN/RBV using response-guided therapy (BOC/RGT); and (3) BOC plus PegIFN/RBV for 44 weeks (BOC/PR48). The management of anemia (hemoglobin [Hb]<10 g/dL) included RBV dose reduction and/or erythropoietin (EPO) use. A total of 1,080…

Male[SDV]Life Sciences [q-bio]MedizinGastroenterologyPolyethylene GlycolsPlaceboschemistry.chemical_compoundHemoglobins0302 clinical medicinehemic and lymphatic diseasesMedicine030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaInterferon-alpha; Serine Proteinase Inhibitors; Proline; Recombinant Proteins; Hematinics; Humans; Ribavirin; Anemia; Antiviral Agents; Drug Therapy Combination; Erythropoietin; Hemoglobins; Adult; Treatment Outcome; Placebos; Polyethylene Glycols; Hepatitis C Chronic; Female; MaleAnemiaHepatitis CHepatitis CRecombinant Proteins3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeCombinationPeginterferon alfa-2b030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsProlineAnemiaInterferon alpha-2PlaceboAntiviral Agentsprotease inhibitor03 medical and health sciencesDrug TherapyInternal medicineBoceprevirRibavirinHumansAdverse effectErythropoietinHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgerychemistryErythropoietinHematinicsbusiness
researchProduct

Two new cases of Thrombocytopenia Absent Radius (TAR) syndrome: Clinical, Genetic and Nosologic Features

1988

Two unrelated children affected by TAR syndrome, autosomic recessive disease with congenital thrombocytopenia and bilateral radial aplasia, are described. In the first case a mild thrombocytopenia has been compatible with a fairly normal life until the second year of age. The other child shows radial aplasia associated with other anomalies of the upper limbs, severe thrombocytopenia and leukemoid reaction. The relationship among TAR syndrome, Fanconi's anemia and Roberts' syndrome are briefly discussed.

Malecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyEctromeliaAnemiaChromosome DisordersGenes RecessiveRadial aplasiaBiologyConsanguinityBilateral radial aplasiahemic and lymphatic diseasesmedicineClinical geneticHumansAbnormalities MultipleChromosome AberrationsPlatelet CountTAR syndromeInfantSyndromemedicine.diseaseThrombocytopeniaDermatologySevere thrombocytopeniaRadiusPediatrics Perinatology and Child HealthFemaleAbsent radiusLeukemoid reactionKlinische Pädiatrie
researchProduct

2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment.

2015

Elevated fetal hemoglobin (HbF) ameliorates the clinical severity of hemoglobinopathies such as β-thalassemia and sickle cell anemia. Currently, the only curative approach for individuals under chronic transfusion/chelation support therapy is allogeneic stem cell transplantation. However, recent analyses of heritable variations in HbF levels have provided a new therapeutic target for HbF reactivation: the transcriptional repressor BCL11A. Erythroid-specific BCL11A abrogation is now actively being sought as a therapeutic avenue, but the specific impact of such disruption in humans remains to be determined. Although single nucleotide polymorphisms in BCL11A erythroid regulatory elements have …

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentImmunologyBiologyBiochemistrySettore MED/38 - Pediatria Generale E SpecialisticaRed Cells Iron and ErythropoiesisInternal medicinehemic and lymphatic diseasesFetal hemoglobinmedicineGene silencingHumansChildNervous System DiseaseFetal HemoglobinNuclear ProteinHematologyNuclear ProteinsCell BiologyHematologymedicine.diseasePhenotypeSickle cell anemiaUp-RegulationTransplantationRepressor ProteinsSettore MED/03 - Genetica MedicaChromosomes Human Pair 22p15-p16.1 microdeletions BCL11A HbF neurologicImmunologyFemaleStem cellChromosome DeletionNervous System DiseasesCarrier ProteinHaploinsufficiencyCarrier ProteinsHumanBlood
researchProduct

Iron deficiency and functional capacity in patients with advanced heart failure with preserved ejection fraction.

2015

Malemedicine.medical_specialty030204 cardiovascular system & hematologyCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansIn patient030212 general & internal medicineProspective StudiesProspective cohort studyAgedHeart FailureAnemia Iron-Deficiencybusiness.industryVO2 maxStroke VolumeStroke volumeIron deficiencymedicine.diseaseHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionCohort studyInternational journal of cardiology
researchProduct

Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome.

2019

Background The Charlson's is the most used comorbidity index. It comprises 19 comorbidities, some of which are infrequent in elderly patients with acute coronary syndrome (ACS), while some others are manifestations of cardiac disease rather than comorbidities. Our goal was to simplify comorbidity assessment in elderly non-ST-segment elevation ACS patients. Methods The study group consisted of 1 training (n = 920, 76 ± 7 years) and 1 testing (n = 532; 84 ± 4 years) cohorts. The end-point was all-cause mortality at 1-year follow-up. Comorbidities were assessed selecting those medical disorders other than cardiac disease that were independently associated with mortality by multivariable analys…

Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsAnemiaEnfermedad cardiovascularAncianoCharlson indexDiseaseComorbidityKaplan-Meier Estimate030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusCause of Deathmental disordersInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityProspective StudiesAcute Coronary SyndromeAgedProportional Hazards ModelsAged 80 and overbusiness.industrymedicine.diseaseComorbiditySpainRisk stratificationCohortCardiopatía coronariaFemalebusinessAncianosEuropean journal of internal medicine
researchProduct

Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.

2019

The composition of lymph nodes in pediatric patients is different from that in adults. Most notably, normal lymph nodes in children contain less macrophages. Therefore, previously described biodistributions of iron oxide nanoparticles in benign and malignant lymph nodes of adult patients may not apply to children. The purpose of our study was to evaluate if the iron supplement ferumoxytol improves the differentiation of benign and malignant lymph nodes in pediatric cancer patients on 18F-FDG PET/MRI. Methods: We conducted a prospective clinical trial from May 2015 to December 2018 to investigate the value of ferumoxytol nanoparticles for staging of children with cancer with 18F-FDG PET/MRI.…

Malemedicine.medical_specialtyAdolescentAnemiaMRI contrast agentMedicine (miscellaneous)030218 nuclear medicine & medical imagingLesioncancer imaging03 medical and health sciences0302 clinical medicineFluorodeoxyglucose F18lymph nodesNeoplasmsferumoxytolmedicineHumansProspective StudiesChildPharmacology Toxicology and Pharmaceutics (miscellaneous)Lymph nodeReceiver operating characteristicbusiness.industryCell Differentiationmedicine.diseasePediatric cancerMagnetic Resonance ImagingFerrosoferric Oxide3. Good healthFerumoxytolmedicine.anatomical_structurePET/MRI030220 oncology & carcinogenesisPositron-Emission TomographyNanoparticlesFemaleRadiologyLymphmedicine.symptomRadiopharmaceuticalsbusinessResearch PaperTheranostics
researchProduct

EARLY EFFICACY OF LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF VISCERAL LEISHMANIASIS

1996

The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory …

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSeverity of Illness IndexGastroenterologyAmphotericin BAmphotericin BInternal medicineAnimalsHumansMedicineLeishmania infantumChildleishmaniasisDrug CarriersChemotherapybiologybusiness.industryPublic Health Environmental and Occupational HealthInfantAnemiaLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureVisceral leishmaniasisItalyChild PreschoolLiposomesImmunologyLeishmaniasis VisceralFemaleParasitologyLiposomal amphotericinHemoglobinBone marrowLeishmania infantumbusinessmedicine.drug
researchProduct